News | Cardiac Diagnostics | August 03, 2017

New Study Focuses on Protein Responsible For Increased Heart Disease Risk

Baylor clinical trial will evaluate potential treatment to reduce lipoprotein(a) levels in the bloodstream

New Study Focuses on Protein Responsible For Increased Heart Disease Risk

August 3, 2017 — A study to reduce the strongest inherited risk factor for heart attack and stroke is now underway at Baylor College of Medicine and other sites across the country and Canada.  

Heart specialists at Baylor say the protein lipoprotein(a), known as Lp(a), has been shown to not only be associated with a higher risk of cardiovascular issues but also to be the cause.

“As high levels of Lp(a) travel through the bloodstream, it collects in the arteries, leading to gradual narrowing of the artery that can limit blood supply to parts of the body including the heart and brain,” said Christie Ballantyne, M.D., professor of medicine and chief of the section of cardiology at Baylor. “It can increase the risk of blood clots, heart attack or stroke and affects 2 to 3 percent of the population, which is about 6 to 10 million Americans.”

While there is a simple blood test to check Lp(a) levels, the challenge is that there are no approved treatments that directly target Lp(a).

The current clinical trial is evaluating a potential treatment to reduce plasma Lp(a) levels in patients with hyperlipoprteinemia(a) and established cardiovascular disease. It is a randomized, double-blind, placebo-controlled study, meaning participants and researchers are not aware of who is receiving the treatment. There also will be a placebo group that is not receiving the treatment although five out of six patients randomized will receive the drug at some dose. Baseline levels will be recorded before, during and at determined intervals to compare group results.

“The goal is to test a therapy that targets messenger RNA, which in turn prevents Lp(a) from being produced at such high levels. So it will block the protein from being made,” Ballentyne said.

“It is still important to talk to your doctor about Lp(a) levels. Until a therapy has been approved the most important part of knowing this number, along with your other risk factors, is understanding your overall risk. Your doctor can help you find the right lifestyle modifications or medications to target the other traditional risk factors such as smoking, diabetes, high cholesterol and blood pressure and family history.”

Those risk factors become even more important to monitor when your Lp(a) levels are high, Ballentyne added.

For more information: www.bcm.edu

Related Content

Livongo Launches Applied Health Signals Product Category
News | Cardiac Diagnostics | November 30, 2018
Healthcare technology company Livongo recently announced the launch of its Applied Health Signals product category,...
HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
Overlay Init